Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

#3017

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Aim(s): A systematic literature review (SLR) was conducted to investigate pt and healthcare practitioner (HCP) perspectives of octreotide and lanreotide.

Materials and methods: MEDLINE/Embase/DARE/the Cochrane Library were searched from database inception to January 2019 with terms for SSAs, NETs, acromegaly, preferences, decision-making and human factors. Key congresses from 2016 onwards and SLR bibliographies were hand-searched. Two reviewers screened articles at title/abstract and full-text stage. Publications fulfilling pre-specified inclusion criteria reported pt or HCP perspectives of octreotide or lanreotide, or any factors affecting SSA treatment perspectives for acromegaly or NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,